Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
JoVE Journal
Immunology and Infection

A subscription to JoVE is required to view this content.
You will only be able to see the first 20 seconds.

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
 

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Article doi: 10.3791/60063
September 17th, 2019 Usage Statistics

Summary September 17th, 2019

Development of a dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF) is novel for the elimination of harmful antibodies. Here, we describe a detailed protocol for the synthesis of DCAF1 molecule, which can selectively block 4G2 antibody to eliminate antibody dependent enhancement effect during Dengue virus infection.

Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
simple hit counter